Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
16 results
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation
D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report
D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months
D3.35 - The influence of birth month on allergen sensitization patterns: A comprehensive analysis of skin prick test results in a large patient cohort
D3.36 - Chronic type non-IgE-mediated gastrointestinal food allergies, Clinical features and unclassified subgroup in the recent cohort
D3.38 - Elucidating the Causes of Discordant Results Between Two Specific IgE Assays Using Component-Resolved Diagnostics and Depletion Testing
D3.39 - Allergic contact dermatitis to oxidized fragrance components: a case of sensitization to hydroperoxides of limonene
D3.44 - Global Trends in Google Search Interest for Allergic Diseases, Diagnostics and Therapies Over Two Decades
D3.46 - Safety of the EAACI risk assessment in hypersensitivity reactions to chemotherapy
D3.47 - Changes in Poaceae and Betulaceae pollen seasons correlate with patient sensitization profiles: a single-centre study over 4 decades
Download the app
The congress at your fingertips
Available on
Download